Isoacteoside exposure decreased A549 lung cancer cell viability dose-dependently after 24 h, with an IC50 of 393.10 ± 15.27 µg/mL. In mouse macrophage RAW 264.7 cells evaluated with Isoacteoside, the reported comparison involving different target compounds of O. vulgaris found no significant proliferation difference versus control at 6.25 μM, 12.5 μM, 25 μM, 50 μM, and 100 μM. Isoacteoside also induced tumor cell apoptosis in HCC cells assessed by flow cytometry. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Cell Viability in Lung Cancer Cells
Cell-based study · A549 lung cancer cell line [1]
A549 lung cancer cells were exposed to Isoacteoside for 24 h, with untreated cells as control. Cell viability decreased dose-dependently, with an IC50 of 393.10 ± 15.27 µg/mL.
Literature-Reported Treatment Conditions
- Treatment concentration
- 12.5, 25, 50, 100, 200, 400, 600, 800, and 1000 µg/mL
- Exposure duration
- 24 h
- Method
- exposure
- Reported limits
- Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Isoacteoside; Compound label in the paper: isoverbascoside
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Materials and Method > 2.9. Determination of Cytotoxicity of C. chinense Leaf Extract and Bioactive Compounds Using Sulforhodamine B (SRB) Assay (S72, S74); 3. Results > 3.8. Determination of Cytotoxicity of C. chinense Leaf Extract and Bioactive Compounds Using Sulforhodamine B (SRB) Assay (S157, S164, S165, S166); Figure 3 legend (S205)
cell viability: cell viability; comparator: untreated cells — 2. Materials and Method > 2.9. Determination of Cytotoxicity of C. chinense Leaf Extract and Bioactive Compounds Using Sulforhodamine B (SRB) Assay (S74); 3. Results > 3.8. Determination of Cytotoxicity of C. chinense Leaf Extract and Bioactive Compounds Using Sulforhodamine B (SRB) Assay (S165, S166); Figure 3 legend (S205)
Macrophage proliferation in an Isoacteoside evaluation
Cell-based study · mouse macrophage RAW 264.7 cells [2]
Isoacteoside was evaluated in mouse macrophage RAW 264.7 cells during 48 h of culture. The reported comparison found no significant difference in proliferation between control cells and cells treated with different target compounds of O. vulgaris at 6.25 μM, 12.5 μM, 25 μM, 50 μM, and 100 μM.
Literature-Reported Treatment Conditions
- Treatment concentration
- 6.25, 12.5, 25, 50, 100, and 200 μM
- Exposure duration
- 48 h of culture
- Method
- added to the culture
- Reported limits
- Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Isoacteoside
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > Anti-Inflammatory Assay > Effects of the Target Compounds of O. vulgaris on Cell Viability (S96, S97, S99); Results > Anti-Inflammatory Assay > Protective Effects of Target Compounds on LPS-Treated RAW 264.7 Cells (S185, S186)
proliferation activity: proliferation activity; comparator: normal control group (without the extract) — Results > Anti-Inflammatory Assay > Protective Effects of Target Compounds on LPS-Treated RAW 264.7 Cells (S185, S186)
Isoacteoside and tumor cell apoptosis
Cell-based study · HCC cells [3]
HCC cells were treated with Isoacteoside, with a negative control for comparison. Flow cytometry showed induced tumor cell apoptosis.
Literature-Reported Treatment Conditions
- Vehicle
- dimethylsulfoxide (DMSO, #D8371, Solarbio)
- Reported limits
- Not stated in the sentences used: dose, route, schedule.
Methods and source locations
Compound reported in the paper: Isoacteoside
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > The combination of isoacteoside and sorafenib significantly increased the therapeutic efficacy of HCC (S119, S120, S127); Methods > Drug, cytotoxicity, and sorafenib resistance testing (S199); Methods > Apoptosis analysis (S209)
Flow cytometry: Flow cytometry; comparator: negative control — Results > The combination of isoacteoside and sorafenib significantly increased the therapeutic efficacy of HCC (S120, S127)